This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maynard, K. Articles by Parsons, P. G. Search for Related Content PubMed PubMed Citation Articles by Maynard, K. Articles by Parsons, P. G.

Cross-Sensitivity of Methylating Agents, Hydroxyurea, and Methotrexate in Human Tumor Cells of the Mer^- Phenotype¹

Queensland Institute of Medical Research, Herston, Queensland, Australia 4006

Five human tumor cell lines of the Mer^- phenotype sensitive to killing by the methylating agent 5-(3-methyl-1-triazeno)imidazole-4-carboxamide were sensitive to hydroxyurea (HU) compared with 15 cell lines resistant to methylating agents (Mer⁺ phenotype). In a study using fewer cell lines, Mer^- cells were also sensitive to methotrexate but not to seven other agents including the antimetabolites 1-ß-D-arabinofuranosylcytosine and 5-fluorouracil. Cells sensitive to HU were designated the Hu^- phenotype. Five autologous Mer⁺ lines, derived in vitro by treating Mer^- lines with methylating agents, did not become resistant to HU or methotrexate (Mer⁺ Hu^- phenotype). All Mer⁺ lines studied had enhanced ability to reactive methylated adenovirus. Adenovirus was inactivated by prolonged treatment with HU, but no enhanced reactivation of HU-treated virus was found in Mer⁺ cell lines. Cell survival after 5-(3-methyl-1-triazeno)imidazole-4-carboxamide treatment was not significantly decreased by HU, nor was replication of methylated adenovirus inhibited by HU in Mer^- or Mer⁺ lines. Replication of untreated adenovirus was poor in Mer^- cells treated with HU, indicating that sensitivity of cells to HU was associated with inhibition of DNA synthesis. These results suggest that cell sensitivity to deoxynucleotide depletion is linked, perhaps coincidentally, to the Mer^- phenotype. The retention of HU and methotrexate sensitivity by cells after development of resistance to 5-(3-methyl-1-triazeno)imidazole-4-carboxamide may have therapeutic implications.

¹ This work was assisted by a grant from the Queensland Cancer Fund.

² To whom requests for reprints should be addressed.

Received 12/17/85. Revised 6/ 3/86. Accepted 7/ 2/86.

This article has been cited by other articles:

				N. Kedei, D. J. Lundberg, A. Toth, P. Welburn, S. H. Garfield, and P. M. Blumberg Characterization of the Interaction of Ingenol 3-Angelate with Protein Kinase C Cancer Res., May 1, 2004; 64(9): 3243 - 3255. [Abstract] [Full Text] [PDF]

				S. M. Ogbourne, A. Suhrbier, B. Jones, S.-J. Cozzi, G. M. Boyle, M. Morris, D. McAlpine, J. Johns, T. M. Scott, K. P. Sutherland, et al. Antitumor Activity of 3-Ingenyl Angelate: Plasma Membrane and Mitochondrial Disruption and Necrotic Cell Death Cancer Res., April 15, 2004; 64(8): 2833 - 2839. [Abstract] [Full Text] [PDF]

				S. M. Ogbourne and T. M. Antalis Characterisation of PAUSE-1, a powerful silencer in the human plasminogen activator inhibitor type 2 gene promoter Nucleic Acids Res., October 1, 2001; 29(19): 3919 - 3927. [Abstract] [Full Text] [PDF]

				C J ELLAWAY, A DUGGINS, V S FUNG, J W EARL, R KAMATH, P G PARSONS, J A ANTONY, and K N NORTH Cockayne syndrome associated with low CSF 5-hydroxyindole acetic acid levels J. Med. Genet., July 1, 2000; 37(7): 553 - 557. [Full Text]